Back to Research Home
NRCNational Research Corp
Health Care · Biotechnology: Commercial Physical & Biological Resarch · Small
$21.93+2.57%
As of 23 Oct 2026Mkt cap $443M
Stage 13
AVOID
Fundamentals
36.3/75
Technical
8.8/15
Independent
45.1/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- +7.8%
- 3M
- +3.1%
- 6M
- +27.3%
- 1Y
- +84.3%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 87.7xHist median 18.8x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 22.7x
- FCF yield
- 4.4%
Quality
- ROIC
- 16.2%
- Operating margin
- 24.6%
- FCF margin
- 11.5%
- Current ratio
- 0.6x
Growth
- Revenue growth
- −4.0%Latest FY YoY
- Revenue CAGR
- −1.8%
- EPS CAGR
- +141.9%
- FCF CAGR
- −21.2%
Capital
- Share-count trend
- −4.7%3Y annualised
- Net debt
- $76M2.9x OCF
Annual trend
- CAGR 2021–2025
- −1.8%
- Latest · 2025
- $0B
- YoY
- −4.0%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-27
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded